Product Description
Vorinostat is a new drug used in the management of cutaneous T cell lymphoma when the disease persists, gets worse or comes back during or after treatment with other medicines. It is an efficacious and well tolerated drug and has been considered a novel drug in the treatment of this condition. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26288427/)
Mechanisms of Action: HDAC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Canada | Chile | Colombia | Dominican Republic | Ecuador | Ireland | Japan | Korea | Mexico | Peru | Russia | Taiwan | United Kingdom | United States
Approved Indications: Lymphoma | T-Cell Cutaneous Lymphoma | T-Cell Lymphoma
Known Adverse Events: Dysgeusia | Thrombocytopenia | Anorexia | Diarrhea
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 2: Adenocarcinoma|Anus Cancer|Cervical Cancer|Head and Neck Cancer|Lung Cancer|Melanoma|Neuroblastoma|Penile Cancer|Primitive Neuroectodermal Tumors|Prostate Cancer|Squamous Cell Carcinoma|Uterine Cancer|Vulvar Cancer
Phase 1: Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RG1123920 | P2 |
Recruiting |
Prostate Cancer|Adenocarcinoma |
2025-12-30 |
|
| Pro00020138 | P1 |
Recruiting |
Breast Cancer |
2025-09-01 |
|
| PEVOsq | P2 |
Active, not recruiting |
Squamous Cell Carcinoma|Head and Neck Cancer |
2024-11-18 |
|
| NANT2017-01 | P1 |
Active, not recruiting |
Neuroblastoma |
2024-02-23 |